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Background. Patients with autoimmune diseases and latent tuberculosis infection (LTBI) are at risk of developing catastrophic
tuberculosis disease following inﬂiximab treatment. Quantiferon-TB gold in-Tube (QTB) has proven a more accurate screening
tool than tuberculin skin test (TST) in adult populations. Objectives. To assess the utility and validity of QTB in children, prior
to treatment with inﬂiximab. Methods. Retrospective cohort of patients started on inﬂiximab following endorsement of QTB as a
screening tool by the NICE guidelines in 2006. Results. Twenty three patients (12 females and 11 males) were included in the study.
A chest radiograph (CXR) and QTB was performed prior to starting inﬂiximab. Fourteen patients had a recorded negative TST
result. One patient had a positive QTB while two had indeterminate results. Their CXRs were not suggestive of TB and TSTs were
negative. The patients with indeterminate results were started on inﬂiximab and had regular clinical assessment for TB disease.
Repeat QTB was negative in one while remained indeterminate in the other. None of our 23 patients developed TB. Conclusion.
QTB is a useful screen tool for LTBI. Indeterminate results warrant careful assessment and re-evaluation, but should not preclude
from initiation of anti TNF treatment.
1.Background
AntitumorNecrosisFactoralpha(TNFα)agentsarearapidly
developing ﬁeld of medicines in pediatric rheumatology. Re-
cent papers have presented the eﬃcacy and eﬀectiveness of
anti-TNFα therapy in disease control and improvement in
quality of life. Agents commonly used include inﬂiximab,
an anti-TNFα chimeric monoclonal antibody, etanercept, an
anti-TNFα receptor fusion IgG protein, and adalimumab, a
humanized monoclonal antibody acting as TNFα receptor
blocker. However, initiation of anti-TNFα treatment is not
without risk. TNF is released by macrophages and is a
potent regulator for granuloma formation and limitation of
the mycobacterium tuberculosis (TB) infection. Anti-TNFα
medications suppress TNF actions and inhibit its restrictive
roleincontrollingTB,thuspotentiallyleadingtoreactivation
of TB disease in those with LTBI. This may have catastrophic
consequences especially in patients with an already dysreg-
ulated and compromised immune system [1]. A tool that
could rule out TB infection prior to anti-TNFα medications
is therefore highly desirable.
Over the last three years the use of Interferon gamma
releasing assays (IGRAs) has been increasingly introduced in
order to verify or rule out latent TB infection (LTBI) [2].
There are voluminous data in the medical literature proving
the superiority of QTB and Elispot in the diagnosis of latent
TB infection in cases where previous methods applied such
as tuberculin skin tests (TSTs) have failed. IGRAs are now
considered sensitive and speciﬁc tools which assist us to
diﬀerentiatebetweenlatentinfection,infectionfromatypical2 ISRN Rheumatology
mycobacteria, and in cases of previous BCG vaccination.
It is found to be signiﬁcantly more sensitive in detecting
LTBI especially in immunocompromised patients. However,
there are no current data to support its use in children with
multisystemic autoimmune diseases.
In the UK the use of IGRA as a screen tool to rule
out LTBI was implemented in National Institute of Clinical
Excellence (NICE) guidelines in March 2006 while its
use prior to commencement of anti-TNFα treatment was
established in 2007.
2. Aim
Our aim is to describe the ﬁndings of QTB test when applied
to a paediatric rheumatology population and to assess the
eﬃcacy of this test versus the methods previously used for
the exclusion of TB infection prior to starting anti-TNFα
treatment.
3.Setting
The setting is a quarterly Paediatric Rheumatology Centre
in the UK caring for all types of rheumatic diseases. In our
hospital QTB was the IGRA of choice used and it became
available in clinical practice in 2005 while the Rheumatology
Team routinely inaugurated QTB to rule out LTBI in 2007.
4. Methods
We have retrospective case study of all patients on inﬂiximab
(the protean anti-TNFα medication used) since 2007 and
their risk assessment for TB infection prior to beginning of
treatment. Patients’ data were collected using the hospital’s
electronic medical data system, systemic review of medical
records, review of patients’ vaccination records (red book),
and personal communication with responsible physician.
5.Analysis
Data were collected regarding age, gender, race, diagnosis,
previous tuberculin skin tests (TSTs) and BCG status, risk
assessment for TB, as well as previous treatment received.
Twenty seven patients had started inﬂiximab treatment since
2007. In four of these patients there was no record of
the QTB test. The remaining 23 patients (12 females, 11
males) had QTB and CXR results recorded. QTB results were
reported as positive, negative, or indeterminate according
to manufacturers (Cellestis Corp. Australia) instructions
using their proprietary software. Median age was 8.9 years
(range from 1.5 to 13 years). Thirteen (55%) patients were
Caucasian, 19% were Afro-Caribbean, and the remaining
were of Asian origin. Their underlying diagnoses were from
wide spectrum of autoimmune diseases including juvenile
idiopathic arthritis (JIA) 34%, uveitis 5%, juvenile dermato-
myositis 26%, vasculitis 9%, systemic onset JIA 17%, and
inﬂammatorybowel disease 9%. Five (22%) patients wereon
methotrexate, and the remaining were on both medications
foroversixmonthspriortoperformingthetest.Lymphocyte
Table 1: Showing cumulative results.
Test/Results Positive Indeterminate Negative Not
recorded
QTB 1 (4.3%) 2 (8.7%) 20 (87%) —
CXR 0 0 23 (100%) 0
TST 0 0 14 (61%) 9 (39%)
BCG 5 (22%)
(scar present) — — 18 (78%)
Risk
assessment 3 (13%) (high) — 20 (87%)
(low) 0
count was recorded at the time of QTB performance and was
withinnormallimitsforallpatients(mean:2.79/mm3;range:
1.59–4.5/mm3; reference range: 1.5–5.0/mm3). Fourteen
(61%) patients had a previous record of a negative TST.
Three (13%) patients were considered high risk, while the
remaining were considered low risk for LTBI. TB risk eval-
uation was performed using the questionnaire formulated
by the United States Pediatric Tuberculosis Collaborative
Group, which was published in 2004 [3].
None of the patients had a positive TST or a chest
radiograph suggestive of TB. Five (22%) patients had a
BCG scar. Twenty (87%) patients had a negative QTB test;
two (8.7%) had an indeterminate result; one (4.3%) has
a positive test (see Table 1). None of these three patients
belonged to the young age group, none had abnormal
ﬁndings on their CXR, and the sputum cultures were
negativeonseveraloccasions.ThepatientwithpositiveQTB,
who belonged to the high-risk group for TB, received six-
month anti-TB treatment following which QTB has become
negative. The patients with indeterminate results were low
risk for LTBI; a repeat QTB test was negative in one while
remained indeterminate in the other. The former event may
be attributed to an improved technique used the second
time. There were no unifying data between the patients with
the indeterminate results and their lymphocyte count was
normal. Elispot was unavailable for cross checking. All 23
patients have been treated with inﬂiximab. The mean dose
was 6mg/kg/dose and mean dose intervals 6.5 weeks (range
from 4 to 9 weeks). Mean duration of treatment was 13
months(range3–24months).Earlywithdrawalofinﬂiximab
was due to treatment failure (failure to control the disease).
None of our 23 patients has developed TB.
6. Discussion
Previousstudieshaveenlightenedthediﬀerenceinspeciﬁcity
and sensitivity of IGRA versus tuberculin skin testing
in immune competent children. Additionally, studies per-
formed on adult populations with underlying autoimmune
conditions proved the superiority of QTB over TST to
various degrees [4, 5]. The literature however is limited to
case reports when it comes to children on anti-TNFα and
risk of TB infection [6], and since immune dysregulation
and autoimmune mechanisms diﬀer, results based on adult
studies cannot be extrapolated directly on the paediatricISRN Rheumatology 3
population. Our study is in agreement with previous studies
showing the inconsistency between TST and QTB tests.
Although our data are not numerically suﬃcient to prove
statistical signiﬁcance, given the rarity of autoimmune
diseases in the paediatric population, there are signiﬁcant
clinical data to support the use of QTB as a valuable
assessment tool for exclusion of TB. Interestingly, even
in patients with known history of BCG vaccination TSTs
were not recorded as positive. Negative TST results may be
attributed to a combination of factors such as concurrent
or recent use of steroids and/or defective delayed type
response to tuberculin. The fact that this is a retrospective
study may explain why 9 (39%) of our patients did not
have a TST test, since it was felt that QTB is a superior
method to exclude LTBI. Positive QTB results should be
regarded as true even in the absence of symptoms or
radiological ﬁndings. Our yield of indeterminate results was
lower than what is mentioned in the literature (8.7% versus
21%). Indeterminate results should be treated cautiously;
patientsrequirephysicalexaminationandriskassessmentfor
LTBI. A recently published study from the same institution
proved that young age and immunosuppression are two
independent risk factors for an indeterminate result [7].
In our cohort, none of the patients who belonged to the
young age group had an indeterminate result irrespectively
of underlying diagnosis or previous treatment received. As
these patients were low risk for TB infection and the rest
of the tests performed were negative, we proceeded with
the inﬂiximab. None of our patients has developed TB
disease. There are limitations in our study mainly due to
the small number of patients and the limited follow-up
period. Previous studies based on adults have shown that TB
reactivation occurs within the ﬁrst 12 weeks after initiation
of treatment and it could be argued that a mean duration of
13 months is not a safe time frame [8]. However the minimal
duration of treatment was three months (12 weeks) which is
the average expected time for TB disease to ﬂare up.
7. Conclusion
PositiveIGRAsshouldbeviewedasevidencethatexposureto
mycobacterium TB has occurred and careful clinical history
and investigations including CXR are required to rule out
active disease. In absence of any evidence of active disease,
careful risk assessment for LTBI must guide further decisions
on treatment.
In general, QTB is a relatively safe and eﬀective method
to screen for LTBI. The lack of a gold standard other than
the development of TB disease is missing which makes
validation of these tests very diﬃcult. Randomized control
trials would be required to ascertain this issue and there
is a study currently undertaken in adults with rheumatoid
arthritis and positive QTB who are given inﬂiximab without
prior anti TB treatment. Nonetheless, such studies would
be hazardous to perform in children bearing in mind the
diﬃculties in proving TB infection as well as the risks
associated with reactivation or primary progression of TB
while immunosupressed, and it would be highly unlikely to
meet standards of ethical approval. However, larger studies
are required and adverse events of TB disease whilst on anti-
TNFα treatment need to be reported.
Key Points
(i) A negative TST in children receiving immunosup-
pressive treatment is not adequate in excluding LTBI.
(ii) Indeterminate QTB results should be viewed cau-
tiously; however they should not compromise the
treatment of the underlying condition.
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